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Fictive Bu dose adjustment recommendation for three patients (Patients 1-3) based on inaccurate Bu quantification methods. A. Arbitrary Bu levels range were set as follows: low (0-500 ng/mL), medium (500-1000 ng/mL) and high (1000-5000 ng/mL). Mean bias for each range was calculated for two laboratories, which did not pass the criteria of acceptance of the cross-validation exercise. They are shown here as Lab 1, 2, and the average of the two laboratories as Lab pooled . The Bu levels obtained by one of the successfully cross-validated laboratories (Lab ref ) were recalculated taking into account the bias of Lab 1, 2, and pooled. B. Bu levels obtained in Lab ref and the fictive ones (Lab 1, 2, and pooled) are shown. Moreover, the related PK parameters and subsequent dose adjustments are shown using WinNonLin one-compartment model. The fictive dose adjustments are observed to likely differ from the ones proposed by Lab ref , up to a 50% decrease of dose recommendation. Note that this is a mathematical fictive example; the expertise of the medical team and clinical interpretation are not taken into account. 
S1A).

Average
PK parameters
Bu levels (ng/mL) Patient 3 (>18 yo, 76.6 kg) Bu plasma Css target of 800 ng/mL. Initial weight-dose 57.5 mg, decreased to 44.3 mg following TDM recommendation.
PK parameters Bu levels (ng/mL)
Below, clinical and demographic information on each studied patient and reference laboratory dose recommendations are given. Patient 1 (10 yo, 33.5 kg) Bu plasma Css target of 800 ng/mL. Initial weight-dose 27 mg, decreased to 16 mg following TDM recommendation.
PK parameters
Bu levels (ng/mL)
Patient 2 (5.5 yo, 15.3kg) Bu plasma Css target between 700-800 ng/mL. Initial weight-dose 12mg, no change following TDM recommendation. Figure S1 . Busulfan Long-term stability A. Long-term Bu stability in plasma (n = 76), Pearson correlation (r 2 ) per year is presented on the plot. B. Bland-Altman plots of differences from observed original and repeat measurements of Bu levels in plasma at time t > 2years (pooled analyses of 2-5 years) and at t = 0. Dotted lines indicate the mean bias (90.5 ng/mL) and the gray zone indicates the limit of agreement (± 1.96 SD). C. Long-term Bu stability on DPS, Pearson correlation (r2) of DPS measured at t = 0 and at t > 2 years (n = 20) is presented on the plot. D. Bland-Altman plots of differences from observed original and repeat measurements of Bu levels of DPS at time t > 2 years (pooled analyses of 2-5 years) and at t = 0. Dotted line indicates the mean bias (281.3 ng/mL) and the gray zone indicates the limit of agreement (± 1.96 SD). Figure S4 . Last recorded Bu steady state plasma concentrations (Css) for all pediatric patients (n=18) sorted by age. The last Bu TDM (Bu plasma level measurement) was performed for 2/18 children at day 1, for 4/18 children at day 2, and 12/18 children at day 3. Average Bu levels (ng/mL) %Difference in Bu levels (ng/mL)
